Published in
Russian Journal of Cardiology, 11(25), p. 4167, 2020
DOI: 10.15829/29/1560-4071-2020-4167
Links
Tools
Resolution of the online meeting of Russian experts on the EMPEROR-REDUCED trial
Journal article published in 2020 by
G. P. Arutyunov 
,
A. G. Arutyunov ,
E. I. Tarlovskaya ,
A. S. Ametov ,
N. G. Vinogradova ,
A. A. Garganeeva ,
M. G. Glezer ,
I. V. Zhirov ,
M. V. Ilyin ,
N. A. Koziolova ,
A. O. Konradi ,
A. Y.-U. Lebedeva ,
Y.-U. M. Lopatin ,
S. V. Nedogoda ,
V. V. Salukhov
and other authors.
,
A. G. Arutyunov ,
E. I. Tarlovskaya ,
A. S. Ametov ,
N. G. Vinogradova ,
A. A. Garganeeva ,
M. G. Glezer ,
I. V. Zhirov ,
M. V. Ilyin ,
N. A. Koziolova ,
A. O. Konradi ,
A. Y.-U. Lebedeva ,
Y.-U. M. Lopatin ,
S. V. Nedogoda ,
V. V. Salukhov
and other authors.
Abstract
At the online meeting held on September 3, 2020, the results of the international multicenter trial EMPEROR-REDUCED were considered. Number of proposals and recommendations for the further study of cardiovascular and renal effects of empagliflozin and its practical use in heart failure patients were agreed.